Pharmacosmos
As of the edition of 20 October 2026, Pharmacosmos runs 6 drugs, 2 of them marketed; it is on route A at 0 targets and on route B at 3 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 4 company names in this family.
- G1 Therapeutics, Inc.: acquired in 2024; successor Pharmacosmos A/S
Drugs by status
| Status | Count |
|---|---|
| Marketed | 2 |
| Active | 1 |
| Stopped | 2 |
| Status not established | 1 |
| Total | 6 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Trilaciclib | Ends 2040 (patent) | 2 |
| Ferric derisomaltose | Ends 2029 (patent) | 2 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 3 targets.
All 3 rows on route A or B
In the product3 company-target rows on route A or B; 0 are not shown here, and no score is.
See all 3 targets where Pharmacosmos needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 17 trials led
- Blood and lymph: 11 trials led
- Nutrition and metabolism: 11 trials led